JPM vs MBI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
MBI exhibits critical financial instability, anchored by a weak Piotroski F-Score of 2/9 and a negative Price-to-Book ratio of -0.13, indicating negative shareholder equity. While the company shows modest year-over-year revenue growth of 15.4%, this is completely offset by a disastrous profit margin of -182.47% and extreme earnings volatility. The lack of a Graham Number or Altman Z-Score, combined with a bearish technical trend (0/100), suggests a high-risk speculative profile. Fundamental health is severely compromised despite a superficial current ratio of 2.77.
Compare Another Pair
Related Comparisons
JPM vs MBI: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and MBIA Inc. (MBI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.